Results 1 to 10 of about 184,141 (176)

Acute massive myelofibrosis with acutelymphoblastic leukemia [PDF]

Turkish Journal of Hematology, 2009
Acute myelofibrosis is characterized by pancytopenia of sudden onset, megakaryocytic hyperplasia, extensive bone marrow fibrosis, and the absence of organomegaly. Acute myelofibrosis in patients with acute lymphoblastic leukemia is extremely rare.
Namık Özbek, Bülent Celasun, Feride Iffet Şahin, Meltem Gülşan, Barış Malbora, Zekai Avcı   +5 more
doaj   +1 more source

Acute lymphoblastic leukemia [PDF]

Pediatric Blood & Cancer, 2021
AbstractThe survival of patients with acute lymphoblastic leukemia (ALL) has improved significantly with the use of intensive multimodality treatment regimens including chemotherapy, high‐dose chemotherapy and stem cell rescue, and radiation therapy when indicated.
John Han‐Chih Chang, Matthew M. Poppe, Chia‐Ho Hua, Karen J. Marcus, Natia Esiashvili   +4 more
  +6 more sources

In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. [PDF]

, 2012
Xenograft mouse models represent helpful tools for preclinical studies on human tumors. For modeling the complexity of the human disease, primary tumor cells are by far superior to established cell lines.
Brentjens, Renier J., Castro Alves, Catarina, Ehrhardt, Harald, Farkasova, Katarina, Groiss, Volker, Horstmann, Martin, Jeremias, Irmela, Ogris, Manfred, Quintanilla-Martinez, Leticia, Schneider, Katja, Terziyska, Nadia, Wagner, Ernst, zur Stadt, Udo   +12 more
core   +16 more sources

Acute Lymphoblastic Leukemia [PDF]

Journal of the National Comprehensive Cancer Network, 2012
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment ...
Joseph C, Alvarnas, Patrick A, Brown, Patricia, Aoun, Karen Kuhn, Ballen, Naresh, Bellam, William, Blum, Michael W, Boyer, Hetty E, Carraway, Peter F, Coccia, Steven E, Coutre, Jennifer, Cultrera, Lloyd E, Damon, Daniel J, DeAngelo, Dan, Douer, Haydar, Frangoul, Olga, Frankfurt, Salil, Goorha, Michael M, Millenson, Susan, O'Brien, Stephen H, Petersdorf, Arati V, Rao, Stephanie, Terezakis, Geoffrey, Uy, Meir, Wetzler, Andrew D, Zelenetz, Maoko, Naganuma, Kristina M, Gregory   +26 more
openaire   +4 more sources

A case of therapy-related acute lymphoblastic leukemia following the treatment of acute myeloid leukemia

Leukemia Research Reports, 2022
Therapy-related acute lymphoblastic leukemia represents a distinct entity associated with inferior survival compared with de novo acute lymphoblastic leukemia.
Sufana Shikdar, Yuan Ying, Mohamad Khawandanah   +2 more
doaj   +1 more source

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. [PDF]

PLoS ONE, 2015
Osteonecrosis is one of the most common, serious, toxicities resulting from the treatment of acute lymphoblastic leukemia. In recent years, pediatric acute lymphoblastic leukemia clinical trials have used discontinuous rather than continuous dosing of ...
Laura B Ramsey, Laura J Janke, Monique A Payton, Xiangjun Cai, Steven W Paugh, Seth E Karol, Landry Kamdem Kamdem, Cheng Cheng, Richard T Williams, Sima Jeha, Ching-Hon Pui, William E Evans, Mary V Relling   +12 more
doaj   +1 more source

Relapsed Acute Lymphoblastic Leukemia

Indian Journal of Pediatrics, 2023
AbstractOutcomes for children with acute lymphoblastic leukemia (ALL) have improved worldwide to >85%. For those who relapse, outcomes have remained static at ~50% making relapsed acute lymphoblastic leukemia one of the leading causes of death in childhood cancers.
Sidhu, Jasmeet, Gogoi, Manash Pratim, Krishnan, Shekhar, Saha, Vaskar   +3 more
openaire   +3 more sources

Adult Acute Lymphoblastic Leukemia [PDF]

Mayo Clinic Proceedings, 2005
Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities.
Shilpa, Paul, Hagop, Kantarjian, Elias J, Jabbour   +2 more
openaire   +3 more sources

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

Haematologica, 2019
The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of patients with acute lymphoblastic leukemia/lymphoma and assessed the in vitro impact ...
Evgeniya Angelova, Charlene Audette, Yelena Kovtun, Naval Daver, Sa A. Wang, Sherry Pierce, Sergej N. Konoplev, Haitham Khogeer, Jeffrey L. Jorgensen, Marina Konopleva, Patrick A. Zweidler-McKay, L. Jeffrey Medeiros, Hagop M. Kantarjian, Elias J. Jabbour, Joseph D. Khoury   +14 more
doaj   +1 more source

Overcoming steroid resistance in T cell acute lymphoblastic leukemia [PDF]

, 2016
In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic ...
Goossens, Steven, Van Vlierberghe, Pieter   +1 more
core   +3 more sources